No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
VRTX240719P477500
- 1.45
- -0.55-27.50%
15min DelayClose Jul 19 16:00 ET
1.45High1.45Low
1.45Open2.00Pre Close5 Volume17 Open Interest477.50Strike Price725.00Turnover306.68%IV3.16%PremiumJul 19, 2024Expiry Date0.00Intrinsic Value100Multiplier-2DDays to Expiry1.45Extrinsic Value100Contract SizeAmericanOptions Type-0.1729Delta0.0166Gamma339.01Leverage Ratio-51.8481Theta-0.0001Rho-58.61Eff Leverage0.0128Vega
Intraday
- 5D
- Daily
News
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $566 From $500
Vertex Pharmaceuticals (VRTX) has an average outperform rating and a price target range of $325 to $589, according to analysts polled by Capital IQ.Price: 490.21, Change: +2.09, Percent Change: +0.43
Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.
Vertex Pharmaceuticals Price Target Raised to $500.00/Share From $462.00 by HC Wainwright & Co.
Vertex Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/19/2024 2.43% HC Wainwright & Co. $462 → $500 Maintains Buy 07/11/2024 -6.79% Morgan Stanley $402 → $45
H.C. Wainwright Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
H.C. Wainwright analyst Andrew Fein maintains $Vertex Pharmaceuticals(VRTX.US)$ with a buy rating, and adjusts the target price from $462 to $500.According to TipRanks data, the analyst has a
Express News | Vertex Pharmaceuticals Inc. : H.c. Wainwright Raises Target Price to $500 From $462
Comments
The 13F filing for the hedge fund led by the late Jim Simons (RIP) just dropped and we got you covered
Here's a breakdown of the biggest moves:
🔴 SOLD (ranked by largest prev. portfolio %)
$Exxon Mobil(XOM.US$ : 0.70%
$Boeing(BA.US$ : 0.43%
$GE Aerospace(GE.US$ : 0.41%
$Alphabet-C(GOOG.US$ : 0.31%
$Netflix(NFLX.US$ : 0.31%
$Disney(DIS.US$ : 0.24%
🟢 NEW (ranked by portfolio %):
$Chevron(CVX.US$ : 0.52% ...
Here's a breakdown of the biggest moves:
🔴 SOLD (ranked by largest prev. portfolio %)
$Exxon Mobil(XOM.US$ : 0.70%
$Boeing(BA.US$ : 0.43%
$GE Aerospace(GE.US$ : 0.41%
$Alphabet-C(GOOG.US$ : 0.31%
$Netflix(NFLX.US$ : 0.31%
$Disney(DIS.US$ : 0.24%
🟢 NEW (ranked by portfolio %):
$Chevron(CVX.US$ : 0.52% ...
+1
18
Keep an eye on these M&As: 👀
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt(ADTX.US$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US$
$Johnson & Johnson(JNJ.US$ to acquire $ShockWave Medical(SWAV.US$
$Vertex Pharmaceuticals(VRTX.US$ to acquire $Alpine Immune(ALPN.US$
$Century Therapeutics(IPSC.US$ to acquire Clade Tx
$Eliem Therapeutics(ELYM.US$ to acquire Tenet Med.
$Incyte(INCY.US$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals(DCPH.US$
...
Onconova Tx merger w/ Trawsfynydd Tx
$Aditxt(ADTX.US$ to acquire Appili Tx
TuHURA Biosciences merger w/ $Kintara Therapeutics(KTRA.US$
$Johnson & Johnson(JNJ.US$ to acquire $ShockWave Medical(SWAV.US$
$Vertex Pharmaceuticals(VRTX.US$ to acquire $Alpine Immune(ALPN.US$
$Century Therapeutics(IPSC.US$ to acquire Clade Tx
$Eliem Therapeutics(ELYM.US$ to acquire Tenet Med.
$Incyte(INCY.US$ to acquire Escient Pharm.
ONO Pharm to acquire $Deciphera Pharmaceuticals(DCPH.US$
...
7
No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals,
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US$ paid $4.9 bil for $Alpine Immune(ALPN.US$
$Gilead Sciences(GILD.US$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
6
$Vertex Pharmaceuticals(VRTX.US$ reported on May 6 first quarter adjusted earnings and revenue that beat analysts' estimates.
The company reported adjusted earnings of $4.76 a share on product revenue of $2.69 billion for the three months that ended March 31. Analysts estimates compiled by LSEG called for adjusted earnings of $4.06 per share and product revenue of $2.58 billion, according to Reuters.
The company kept its pr...
The company reported adjusted earnings of $4.76 a share on product revenue of $2.69 billion for the three months that ended March 31. Analysts estimates compiled by LSEG called for adjusted earnings of $4.06 per share and product revenue of $2.58 billion, according to Reuters.
The company kept its pr...
4
Read more
淡定的惠特莫爾 : Last time you asked me to buy sofi? A lot of falls
淡定的惠特莫爾 :
EZ_moneyOP 淡定的惠特莫爾: Sofi all you have to do is buy under 7 and hold. you don't lose unless you sell for a lost. hold until above 7 easy
淡定的惠特莫爾 EZ_moneyOP: Oh! Thank you
EZ_moneyOP 淡定的惠特莫爾:
View more comments...